Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Neuro-Oncology|February 6, 2026
Neurofibromatosis type 1 plexiform neurofibromas: Integrating treatment across pediatric and adult populationsAmy E Armstrong, Andrea M Gross, Laura J Klesse, et al.
ACS Nano|January 12, 2017
One-Component Supramolecular Filament Hydrogels as Theranostic Label-Free Magnetic Resonance Imaging AgentsLye Lin Lock, Yuguo Li, Xinpei Mao, et al.
Cancers|June 26, 2025
The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient ModelPei-Yu Hung, Jessica A Moerland, Ana S Leal, et al.
Theranostics|May 17, 2021
Deuterium oxide as a contrast medium for real-time MRI-guided endovascular neurointerventionLin Chen, Jing Liu, Chengyan Chu, et al.
Nature|December 14, 2018
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndromeVerena Staedtke, Ren-Yuan Bai, Kibem Kim, et al.
Oncotarget|April 8, 2015
Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in ratsVerena Staedtke, Ren-Yuan Bai, Weiyun Sun, et al.
The Journal of Investigative Dermatology|June 9, 2023
Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous NeurofibromasIna Ly, Carlos G Romo, Sally Gottesman, et al.
The Journal of Investigative Dermatology|May 28, 2023
RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological InsightsSteven D Rhodes, Frank McCormick, Ross L Cagan, et al.
NMR in Biomedicine|November 15, 2021
Dynamic contrast-enhanced CEST MRI using a low molecular weight dextranZheng Han, Chuheng Chen, Xiang Xu, et al.
Clinical Trials (London, England)|November 8, 2023
Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trialsVerena Staedtke, Kara Anstett, David Bedwell, et al.
Pageof 5